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Abstract
Background: The challenge of Bipolar Disorder (BD) treatment is due to the complexity of the disease. Current 
guidelines represent an effort to help clinicians in their everyday practice but still have limitations, specially concerning 
to long term treatment. LICAVAL (efficacy and tolerability of the combination of LIthium and CArbamazepine compared to 
lithium and VALproic acid in the treatment of young bipolar patients) study aim to evaluate acute and maintenance phase 
of BD treatment with two combined drugs.
Methods: LICAVAL is a single site, parallel group, randomized, outcome assessor blinded trial. BD I patients according 
to the DSM-IV-TR, in depressive, manic,/hypomanic or mixed episode, aged 18 to 35 years are eligible. After the 
diagnostic assessments, the patients are allocated for one of the groups of treatment (lithium + valproic acid or lithium 
+ carbamazepine). Patients will be followed up for 8 weeks in phase I (acute treatment), 6 months in phase II 
(continuation treatment) and 12 months in phase III (maintenance treatment). Outcome assessors are blind to the 
treatment. The main outcome is the evaluation of changes in mean scores on CGI-BP-M between baseline and 
endpoint at the end of each phase of the study.
Results: LICAVAL is currently in progress, with patients in phase I, II or III. It will extended until august 2012.
Conclusions: Trials comparing specific treatments efficacy in BD (head to head) can show relevant information in 
clinical practice. Long term treatment is an issue of great important and should be evaluated carefully in more studies 
as long as BD is a chronic disease.
Trial registration: ClinicalTrials.gov Identifier: NCT00976794
Background
Bipolar Disorder (BD) treatment is a topic in evolution as
long as the understanding of the clinical features, and
possible pathophysiology, still progress. Due to multivari-
ate factors associated with its cause and the variability of
clinical presentations it's hard to determine a specific
treatment with best outcome (efficacy and tolerability).
Some difficulties in the BD treatment include: delay in
diagnosis, high levels of comorbidity, frequent treatment
nonadherence and high risk of relapse/recurrence
(mainly in the presence of residual symptoms) [1].
Most treatments focus on acute phase and the measure
of response as a reduction in symptoms of at least 50%
f r o m  b a s e l i n e .  I n  f a c t ,  a  n u m b e r  o f  p a t i e n t s  w h o
responded to treatment continue to experience signifi-
cant subsyndromic symptoms. A small number of studies
reported remission rates, which mean at least 2 months
with no significant signs or symptoms of the disorder [2].
Fewer studies reported remission during acute phase
through maintenance phase of treatment and its predic-
tors [3] what is of great clinical significance. Recent data
showed that BD treatment in special conditions was asso-
ciated with full remission in only half of the patients and
that nearly half of the recovered patients relapsed at least
once during the two year of follow up [4]. Maintenance
treatment is necessary in BD due to its great mortality,
morbidity risk and social and professional impairment
associated with its poorer outcome [5].
Lithium is first line choice for the maintenance treat-
ment of BD, mainly for classic (euphoric) mania and bipo-
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lar depression according to many open controlled studies,
with additional clinical effects such as: antisuicidal prop-
erties; augmentation and treatment of acute unipolar
depression and recurrent depression [6]. The accumulat-
ing data tend to support its specificity in psychiatric
usage, specially in those patients with "classic" BD. Avail-
able clinical trial suggest that better response to valproate
are related to dysphoric or mixed episodes and rapid
cycling patients [7]. Recently, valproate evidenced bene-
fits on depressive aspects of BD both on acute and pro-
phylactic use [8]. Carbamazepine is associated with
better response in: not receiving treatment with mood
stabilizers previously; atypical symptoms and signs; dys-
phoric and rapid cycling patients; treatment resistance to
lithium therapy; under 30 years; no family history of BD
[7]. Carbamazepine and valproate appear to be effective
in the prophylactic treatment of bipolar disorder, espe-
cially in combination with lithium, although further stud-
ies are desirable [9].
In Brazil lithium is the first treatment choice in all BD
phases representing an appropriate treatment of accessi-
ble cost. Treatment in the Brazilian Public Health System
(Sistema único de Saúde - SUS) - have financial limita-
tions once atypical antipsychotics and some anticonvul-
sants are not available for use in BD. Therefore, the most
used treatments for the general population present
smaller number of controlled studies in relation to the
newest medications in which the pharmaceutical indus-
try has interest in spreading. Although medications such
as lithium, valproic acid and carbamazepine have been
used for a long time, studies comparing effectiveness and
o t h e r  o u t c o m e  m e as u r e s,  as  w e l l  as  da ta  o f  l o n g  t e rm
combination treatment can still help the adaptation of the
public health politics to the patient's real needs (Taveira
and Moreno: Survey on treatment of bipolar disorder in
Brazil: psychiatrists' epidemiology, prescription drugs
and impact on heath policies. Submitted.)
Methods
LICAVAL Project
LICAVAL (efficacy and tolerability of the combination of
LIthium and CArbamazepine compared to lithium and
VALproic acid in the treatment of young bipolar patients)
is a randomized trial designed to evaluate two combined
drugs in the treatment of bipolar I patients.
Design of LICAVAL
The key points of LICAVAL Project come from the ratio-
nale described above. We considered the disorder as a
whole, that is, different clinical presentations (such as
depression, mania or mixed episodes) are receiving the
same treatment. The treatment focus is relapse/recur-
rence prevention and not treating a particular phase.
Patients should have a long term follow up as BD is a
chronic and recurrent disorder.
This a single site, parallel group, randomized, outcome
assessor blinded trial. The study protocol was reviewed
and approved by the appropriate institutional review
board (Protocol number 0820/08) in accordance with the
standards and guidelines established in the current
amendment of the Declaration of Helsinki, and consistent
with good clinical practice and applicable regulatory
requirements. Written informed consent was obtained
from all patients prior to any study-related activities. All
p h a s e s  o f  L I C A V A L  h a v e  t h e i r  m e t h o d o l o g i c a l  d e t a i l s
presented according to Consolidated Standard of Report-
ing Trials (CONSORT) 2010 Statement [10].
Interventions
After the diagnostic assessments, the patients are allo-
cated for one of the following groups of treatment:
Group I: lithium + valproic acid
Group II: lithium + carbamazepine
Lithium: Starting at 600 mg daily, dose weekly adjusted
according to blood serum level (0,6 -1,2mEq/l), efficacy
and tolerability
Valproic acid: Starting at 500 mg daily, dose weekly
adjusted according to blood serum level (50 and 125 μg/
ml), efficacy and tolerability
Carbamazepine: Starting at 200 mg daily and getting
600 mg daily at the end of the first week. Dose weekly
adjusted according to blood serum level (8 and 12 μg/ml),
efficacy and tolerability
Concomitant medications are permitted and may con-
tinue until remission or symptomatic control needed
according to clinical criteria:
•Lorazepam - 0,5 - 4 mg/day orally
•Sertraline - 50 - 200 mg/day orally
Eligibility
Patients are recruited in the Institute of Psychiatry, of the
Clinical Hospital of the University of Sao Paulo, School of
Medicine. BD I patients according to the DSM-IV-TR [2],
in depressive, manic,/hypomanic or mixed episode, aged
18 to 35 years are eligible. Patients with psychotic symp-
toms will be included and will not be stratified. Patients
with co-morbid conditions are allowed to participate due
to the study clinical reality approach ("more likely natu-
ralistic study").
The patient or his/her legal representative should
understand the nature of the study and sign the Informed
Consent.
Eligible patients under pharmacological treatments
proceed to a wash-out period according to the medica-Campos et al. Trials 2010, 11:72
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tion in use: 1 week for antidepressants (except fluoxetine
and irreversible MAOI), antipsychotics (except clozap-
ine), lithium, valproate, carbamazepine and other anti-
convulsants; 2 weeks for irreversible MAOI; 4 weeks for
fluoxetine and clozapine.
Sample Size and Randomization
Sample size was calculated comparing the mean differ-
ence in CGI-BP-M scores between baseline and endpoint
for the two groups. If we compare this using a Student's t
test we find that with 50 patients (25 in each group) we
achieve 80% power (in a 5% of significance level test) to
detect a difference of 0.8 standard deviation, which can
be considered a large effect size [11]. Due to the explor-
atory nature of this study and the difficulties of compli-
ance in a long term trial, this seems to be an acceptable
value.
The random allocation sequence was computer gener-
ated by a biostatistician. Patients were enrolled by clini-
cians who have their code revealed by the research
monitor when assigned to interventions. Blinding the
outcome assessor is done keeping their evaluation inde-
pendent to the clinician.
Study phases
Patients will be followed up for 8 weeks in phase I (acute
treatment), 6 months in phase II (continuation treatment)
and 12 months in phase III (maintenance treatment).
Scales raters will be blind to the treatment. During phase
II and III will continue only patients that achieve
response, measured according to initial symptoms score
in phase I. Patients with a new episode of any polarity
detected in two consecutives visits will be discontinued
from the study.
The definition of clinical course is defined according to
Hirschfeld et al (2007) [12], Bauer et al (2007) [13] and
Tohen et al (2009) [14]:
Non response: reduction ≤ 25% in severity of symp-
toms;
Partial response: improvement of symptoms between
26 and 49%;
Response: reduction ≥ 50% in severity of symptoms;
Remission: minimal or no symptoms for at least 1 week;
Sustained remission: at least 8 weeks of remission;
Relapse/recurrence: return of the criteria for the syn-
drome;
Roughening: return of symptoms in a subsyndromal
level.
Primary outcomes
Primary outcome will be the evaluation of changes in
mean scores on CGI-BP-M between baseline and end-
point at the end of each phase of the study.
Secondary outcomes
Secondary outcome will include the proportion of
patients that achieve remission and response to each
treatment at the end of each phase of the study, according
to improvement in rating scales (HAM-D; MADRS;
YMRS) and in clinical global impression specific for BD
(CGI-BP-M) [15]. The CGI-BP-M is a clinician rating
scale modified for Bipolar Disorder concerning to treat-
ment response and consists of 3 sub-scales evaluating the
severity of mania, depression and the whole disease
symptoms.
Other outcome parameters are: safety and tolerability;
quality of life and social adjustment; and cognitive
impairment. These parameters will be evaluated compar-
ing the endpoint measures of each phase with baseline.
Safety and tolerability: according to the clinical evalua-
tion of adverse effects and the measure on the UKU side
effect rating scale [16]. UKU consists of 48 items clinician
rated evaluating side effects in psychic, neurologic, auto-
nomic and other domains. Quality of life and social
adjustment: measure with the WHOQoL-BREF [17] and
Social Adjustment Scale [18]. These instruments were
translated and validated to Portuguese [19,20]. WHO-
QOL-BREF is a self report 26 items scale comprising 4
domains: physical, psychological, social and environ-
ment. The Social Adjustment Scale is a self report 54
questions instrument that measures instrumental and
expressive role performance over the past two weeks.
Cognitive impairment: neuropsychological tests (Wis-
consin Card Sorting Test [21], Stroop Color Word Test
[21], WASI - Wechsler Abbreviated Scale of Intelligence
[22], Trail Making Test [21] and others), which are avail-
able in Portuguese. All investigators received appropriate
training, and inter-rater reliability is periodically
assessed.
Planned Analyses
The primary analysis will be the evaluation of the mean
scores on CGI-BP-M between baseline and endpoint in
both groups. We will also evaluate differences comparing
the two groups of treatment concerning total number of
patients in full remission at the end of the study and the
reason and time to drop out. Continuous data will be rep-
resented by mean and standard deviation (SD). Categori-
cal variables will be described by table of frequencies.
The results of all statistical comparisons of the treatment
groups will be presented as a 2-sided p values rounded to
3 decimal places. The criterion for statistical significance
in all comparisons will be p ≤ 0.05.
Continuous variables will be compared using repeated
measures analysis of variance (ANOVA), with group of
treatment and study phase as factors. Rates of response,
remission and drop-outs will be compared between theCampos et al. Trials 2010, 11:72
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two groups using a Pearson's X2 test for categorical data.
Dichotomous measures will also be compared using odds
ratios and 95% confidence limits.
The correlation of clinical issues, quality of life, social
adjustment and cognitive impairment will be evaluated
by Pearson's correlation.
Results
Current Status of LICAVAL
LICAVAL is currently in progress, with patients in phase
I or II. It will extend during the next two years.
Discussion
Trials comparing specific treatments efficacy in BD (head
to head) can show relevant information in clinical prac-
tice.
Usual limitations in clinical trials are:
- Specific clinical forms of BD (Mania/Mixed or 
Depression) for each treatment tested.
- There is little information about how the treatment 
in acute phase should progress to maintenance or 
which factors from the acute treatment could predict 
recurrences during maintenance treatment.
- The heterogeneity of patients, considering course of 
illness (chronic versus non chronic), in clinical trials 
can shadow important treatment implications for 
specific populations (younger versus older, for exam-
ple).
Conclusions
Due to the substantial increase in treatment options,
guidelines and algorithms are used in an effort to enhance
the cost-effectiveness of care by reducing the number of
treatment options [13]. Although limitations can be
addressed in the use of these algorithms, they represent
the available data concerning the levels of evidence of
each treatment option.
Lithium, anticonvulsants and atypical antipsychotics
appear in all guidelines with different recommended use
according to clinical presentation, showing different lev-
els of efficacy. Lithium, Valproate and Carbamazepine
h a v e  s t r o n g  e v i d e n c e  o f  b e n e f i t s  i n  B D  t r e a t m e n t ,
although each of them have its particularities. Evidence
based knowledge concerning maintenance treatment
with combination treatment are still needed in clinical
practice.
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